...BRCA1/2 mutations. PARPi leads to an increase in the expression of tumor neoantigen, interferon (IFN), and programmed ce...
...BRCA1/2 wild-type ovarian cancer was performed. Treatment with harmine inhibited HR activity in a dose-dependent manner ...
...BRCA1 (1%; 95% CI: 1%-3%), BRCA2 (1%; 95% CI: 1%-3%), and TP53 (1%; 95% CI: 0%-3%). Patients with P/LP variants in DNA d...
...BRCA1/2 alterations who did not receive prior ARPI, the combination of PARPi and ARPI (talazoparib + enzalutamide, olapa...
Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment landscape for patients suffering from ...
...BRCA1/2 and ADAR1 are synthetically lethal, and that ADAR1 activity is upregulated in BRCA1/2-mutant cancers. ADAR1 depl...
...BRCA1/2 and additional genes causative of HRD. Using this reference, the new biomarker fdeam defined as frequency of C >...
...BRCA1)-activating protein 1 (BAP1) and one of three additional sex combs-like 1-3 (ASXL1-3) proteins. A plant homeodomai...
...BRCA1/2 mutations (71%). The random forest model achieved 80% accuracy in mortality prediction (AUC = 0.78) and 75% accu...
...BRCA1 positive status among the breast cancer patients. The present study identified for the first time the association ...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
